相似文献
1
Improved method to calculate the antibody avidity index.
J Clin Lab Anal. 2007;21(3):201-6. doi: 10.1002/jcla.20172.
2
Use of IgG avidity ELISA to differentiate acute from persistent infection with Salmonella Dublin in cattle.
J Appl Microbiol. 2006;100(1):144-52. doi: 10.1111/j.1365-2672.2005.02758.x.
3
Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays.
Clin Vaccine Immunol. 2007 Apr;14(4):397-403. doi: 10.1128/CVI.00241-06. Epub 2007 Feb 7.
4
Estimation of the avidity of antibodies in polyclonal antisera against Streptococcus pneumoniae type 3 by inhibition ELISA.
Mol Immunol. 1989 Mar;26(3):269-74. doi: 10.1016/0161-5890(89)90080-1.
5
Avidity as a criterion for diagnosis of human strongyloidiasis increases specificity of IgG ELISA.
Diagn Microbiol Infect Dis. 2017 Dec;89(4):262-264. doi: 10.1016/j.diagmicrobio.2017.08.008. Epub 2017 Aug 26.
6
Evaluation of the indirect and IgM-capture anti-human cytomegalovirus IgM ELISA methods as confirmed by cytomegalovirus IgG avidity.
Microbiol Immunol. 2019 May;63(5):172-178. doi: 10.1111/1348-0421.12683. Epub 2019 May 22.
7
[The value of the immunoglobulin G avidity test for the serologic diagnosis of brucellosis].
Mikrobiyol Bul. 2003 Oct;37(4):261-7.
8
Evaluation of specific immunoglobulin G avidity enzyme linked immunosorbent assay (IgG avidity ELISA) in diagnosis of early and chronic Schistosomiasis mansoni.
J Egypt Soc Parasitol. 1998 Dec;28(3):739-52.
9
Assessment of IgG avidity against pertussis toxin and filamentous hemagglutinin via an adapted enzyme-linked immunosorbent assay (ELISA) using ammonium thiocyanate.
J Immunol Methods. 2013 Jan 31;387(1-2):36-42. doi: 10.1016/j.jim.2012.09.008. Epub 2012 Sep 27.
10
Urea dilution of serum for reproducible anti-HSV1 IgG avidity index.
BMC Infect Dis. 2019 Feb 14;19(1):164. doi: 10.1186/s12879-019-3769-x.
引用本文的文献
1
IgA-driven neutrophil activation underlies post-Zika severe dengue disease in humans.
medRxiv. 2025 Mar 24:2025.02.11.25322002. doi: 10.1101/2025.02.11.25322002.
2
Cross-species immunoprotective antigens (subolesin, ferritin 2 and P0) provide protection against Rhipicephalus sanguineus sensu lato.
Parasit Vectors. 2024 Jan 3;17(1):3. doi: 10.1186/s13071-023-06079-3.
3
Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine.
Malar J. 2023 Dec 9;22(1):374. doi: 10.1186/s12936-023-04798-7.
4
SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines.
Hum Vaccin Immunother. 2023 Aug 1;19(2):2215677. doi: 10.1080/21645515.2023.2215677. Epub 2023 Jun 1.
5
Humoral immunity in dually vaccinated SARS-CoV-2-naïve individuals and in booster-vaccinated COVID-19-convalescent subjects.
Infection. 2022 Dec;50(6):1475-1481. doi: 10.1007/s15010-022-01817-8. Epub 2022 Apr 11.
6
Formation and Expansion of Memory B Cells against Coronavirus in Acutely Infected COVID-19 Individuals.
Pathogens. 2022 Jan 29;11(2):186. doi: 10.3390/pathogens11020186.
7
Soluble antigens derived from elicit protective immunity in three animal models without inducing hypersensitivity.
Cell Rep Med. 2021 Dec 6;2(12):100461. doi: 10.1016/j.xcrm.2021.100461. eCollection 2021 Dec 21.
8
Chaotropic Perturbation of Noncovalent Interactions of the Hemagglutinin Tag Monoclonal Antibody Fragment Enables Superresolution Molecular Census.
ACS Nano. 2022 Jan 25;16(1):129-139. doi: 10.1021/acsnano.1c04237. Epub 2021 Nov 19.
9
Modified ELISA for antibody avidity evaluation: The need for standardization.
Biomed J. 2021 Aug;44(4):433-438. doi: 10.1016/j.bj.2020.10.009. Epub 2020 Oct 27.
10
Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery.
Vaccines (Basel). 2021 Jun 11;9(6):642. doi: 10.3390/vaccines9060642.
本文引用的文献
1
Humoral immune response to primary rubella virus infection.
Clin Vaccine Immunol. 2006 Mar;13(3):380-6. doi: 10.1128/CVI.13.3.380-386.2006.
2
A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens.
Vaccine. 2006 Mar 6;24(10):1680-6. doi: 10.1016/j.vaccine.2005.09.046. Epub 2005 Oct 6.
3
Effect of a booster dose of serogroup B meningococcal vaccine on antibody response to Neisseria meningitidis in mice vaccinated with different immunization schedules.
FEMS Immunol Med Microbiol. 2005 Apr 1;44(1):35-42. doi: 10.1016/j.femsim.2004.11.013.
4
Porin A-specific antibody avidity in patients who are convalescing from meningococcal B disease.
Pediatr Res. 2005 Jul;58(1):149-52. doi: 10.1203/01.PDR.0000156372.13569.08. Epub 2005 Mar 17.
5
Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
FEMS Immunol Med Microbiol. 2004 Jul 1;41(3):205-10. doi: 10.1016/j.femsim.2004.03.005.
6
Comparison of two commercially available avidity tests for toxoplasma-specific IgG antibodies.
Arch Med Res. 2002 Nov-Dec;33(6):520-3. doi: 10.1016/s0188-4409(02)00411-3.
7
Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.
Infect Immun. 2002 Feb;70(2):584-90. doi: 10.1128/IAI.70.2.584-590.2002.
8
Production of low-avidity antibody by infants after infection with serogroup B meningococci.
Lancet. 2000 Dec 16;356(9247):2065-6. doi: 10.1016/S0140-6736(00)03405-X.
9
Vaccines for prevention of meningococcal disease.
Pediatr Infect Dis J. 2000 Apr;19(4):333-44; quiz 345. doi: 10.1097/00006454-200004000-00015.
10
A new method with general diagnostic utility for the calculation of immunoglobulin G avidity.
Clin Diagn Lab Immunol. 1999 Sep;6(5):725-8. doi: 10.1128/CDLI.6.5.725-728.1999.
Zotero 插件